RECURSION PHARMACEUTICALS, INC. Operating Expenses
RECURSION PHARMACEUTICALS, INC. (RXRX) reported Operating Expenses of $192.95 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-23.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2022-03-23
- RECURSION PHARMACEUTICALS, INC. operating expenses for the quarter ending 2021-12-31 was $67.49M, a 138.73% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating expenses for the quarter ending 2021-09-30 was $48.94M, a 108.25% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating expenses for the quarter ending 2021-06-30 was $43.48M, a 136.25% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating expenses for the quarter ending 2021-03-31 was $33.05M, a 79.57% increase year-over-year.
- RECURSION PHARMACEUTICALS, INC. operating expenses for fiscal 2021 was $192.95M, a 117.84% increase from fiscal 2020.
- RECURSION PHARMACEUTICALS, INC. operating expenses for fiscal 2020 was $88.58M, a 36.78% increase from fiscal 2019.
- RECURSION PHARMACEUTICALS, INC. operating expenses for fiscal 2019 was $64.76M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2021-12-31 | $67.49M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $116.43M derived: sum of 2 quarters · filed 2022-03-23 | $159.91M derived: sum of 3 quarters · filed 2022-03-23 | $192.95M 10-K · filed 2022-03-23 |
| 2021-09-30 | $48.94M 10-Q · filed 2021-11-10 | $92.41M derived: sum of 2 quarters · filed 2021-11-10 | $125.46M 10-Q · filed 2021-11-10 | $153.73M derived: sum of 4 quarters · filed 2022-03-23 |
| 2021-06-30 | $43.48M 10-Q · filed 2021-08-13 | $76.52M 10-Q · filed 2021-08-13 | $104.80M derived: sum of 3 quarters · filed 2022-03-23 | $128.29M derived: sum of 4 quarters · filed 2022-03-23 |
| 2021-03-31 | $33.05M 10-Q · filed 2021-05-12 | $61.32M derived: sum of 2 quarters · filed 2022-03-23 | $84.82M derived: sum of 3 quarters · filed 2022-03-23 | $103.22M derived: sum of 4 quarters · filed 2022-03-23 |
| 2020-12-31 | $28.27M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-23 | $51.77M derived: sum of 2 quarters · filed 2022-03-23 | $70.17M derived: sum of 3 quarters · filed 2022-03-23 | $88.58M 10-K · filed 2022-03-23 |
| 2020-09-30 | $23.50M 10-Q · filed 2021-11-10 | $41.90M derived: sum of 2 quarters · filed 2021-11-10 | $60.30M 10-Q · filed 2021-11-10 | |
| 2020-06-30 | $18.40M 10-Q · filed 2021-08-13 | $36.81M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $18.40M 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $64.76M 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |